TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21705273
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (titrated from 0.5 mg/24 h to a maximum of 4 mg/24 h)
Study: 25773763
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (4 mg/24 h)
Study: 21705273
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (1-3 mg/24 h)
Study: 19508310
Drug: Moisturizer (urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizer (urea containing), applied twice daily during a 26-week maintenance phase
Study: 19508310
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated areas)
Study: 12542609
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine (3 standard injections at 0, 30, and 60 days)
Study: 12690275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication or vaccination)
Study: 9379571
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution flush (3 ml)
Study: 9379571
Drug: Heparin solution
Normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin solution flush (3 ml of 10 units heparin/ml normal saline)
Study: 9379571
Drug: Cost-saving implications
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cost-saving implications of normal saline solution
Study: 8405007
Drug: Oxcarbazepine 150
Normalized name: oxcarbazepine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 150 mg b.i.d.
Study: 8405007
Drug: Oxcarbazepine 300
Normalized name: oxcarbazepine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 300 mg b.i.d.
Study: 3485119
Drug: Chewable aspirin
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Chewable Aspirin]
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable aspirin (10-15 mg/kg)
Study: 3485119
Drug: Acetaminophen (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10-15 mg/kg)
Study: 31380003
Drug: Aggressive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fluid therapy with 20 mL/kg of ringer lactate infusion within 90 minutes before ERCP and 3 mL/kg/h during ERCP followed by 3 mL/kg/h up to 8 hours
Study: 31380003
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 1.5 mL/kg of ringer lactate infusion during ERCP up to 8 hours later
Study: 21146749
Drug: HGF gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF gene therapy
Study: 20689464
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg/day
Study: 17613583
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D supplements
Study: 9565804
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - 150 mg/kg bolus in 250 ml of 5% dextrose followed by continuous infusion of 12 mg/kg per hour in 500 ml of 5% dextrose over 24 hours for a minimum of 3 days up to a maximum of 5 days.
Study: 9565804
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - equal volume of placebo administered for the same duration as NAC.
Study: 3357653
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) patch 50 micrograms/day
Study: 28768538
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) treatment
Study: 26201713
Drug: Rifaximin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (400 mg thrice a day)
Study: 26201713
Drug: Lactulose (30-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (30-120 ml/day)
Study: 21748313
Drug: Oral fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluids only
Study: 21748313
Drug: Intravenous Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ringer lactate at 125 ml/h
Study: 21748313
Drug: Intravenous Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ringer lactate at 250 ml/h
Study: 17634541
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of IFN gamma receptor
Study: 17634541
Drug: Complete loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete loss of IFN gamma receptor
Study: 10917002
Drug: 2.5 mEq/l
Normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mEq/l dialysate calcium (DCa)
Study: 10917002
Drug: 3 mEq/l
Normalized name: physiological irrig soln no.1 140 mEq-5 mEq-3 mEq-98 mEq-27 mEq-23 mEq/L IRRIGATION SOLUTION, IRRIGATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mEq/l dialysate calcium (DCa)
Study: 2056888
Drug: L-sulpiride (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride (150 mg po/die)
Study: 2056888
Drug: Racemic sulpiride
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic sulpiride (300 mg po/die)
Study: 6318655
Drug: Intranasal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal human interferon alpha A
Study: 27094556
Drug: brush‐plus‐rinse treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: brush‐plus‐rinse treatment
Study: 27094556
Drug: brush‐alone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: brush‐alone treatment
Study: 17848748
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid (4 mg, iv, every 28 d)
Study: 9061712
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity assessment using the Bergman minimal model
Study: 9061712
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity at 12 months
Study: 8141692
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg twice daily)
Study: 7881704
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg once daily)
Study: 3533455
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (100 mg)
Study: 3533455
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (0.4 mg)
Study: 2484920
Drug: dihydroquinidine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydroquinidine (900 mg/day)
Study: 2484920
Drug: quinidine (1,650
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinidine (1,650 mg/day)
Study: 29275580
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: dose-dense TEC× 4 every 2 weeks with G-CSF
Study: 29275580
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: sequential EC× 4 (dose-dense)-T × 4 every 2 weeks
Study: 29275580
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: concurrent TEC× 4 every 3 weeks
Study: 29275580
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: sequential EC× 4-T × 4 every 3 weeks
Study: 23274145
Drug: Atorvastatin test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin test formulation (generic) 20 mg per day for 8 weeks
Study: 23274145
Drug: Atorvastatin reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reference formulation (original) 20 mg per day for 8 weeks
Study: 23274145
Drug: Atorvastatin test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin test formulation
Study: 23274145
Drug: Atorvastatin reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reference formulation
Study: 15281283
Drug: Anticancer drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticancer drugs (33% off label use)
Study: 10667492
Drug: IVIG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (1 g/kg in four divided doses on days 1, 2, 3, and 6)
Study: 8364347
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg S(+) OXP daily
Study: 8364347
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg R(‐) OXP daily
Study: 8364347
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg S(+) OXP single dose (normal controls)
Study: 8364347
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg R(‐) OXP single dose (normal controls)
Study: 3090864
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (low to moderate doses)
Study: 3090864
Drug: Chlordiazepoxide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (10 mg tid, active placebo)
Study: 20144173
Drug: Non-medication group
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-medication group
Study: 30952575
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla-300) managed by nurse-assisted patients
Study: 30952575
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla-300) managed by physicians
Study: 23020760
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L beetroot (BR) juice
Study: 23020760
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L placebo (PLA) drink with blackcurrant juice
Study: 16293396
Drug: 6-week combined
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week combined treatment approach using vocal function exercises (VFEs) and vocal hygiene (VH) education
Study: 12898761
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection with 1.0 ml of 2% chitosan
Study: 12898761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 12.5 mg of prednisolone
Study: 11303537
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 3 ml 1% l-menthol solution
Study: 11303537
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation of 3 ml 0.05% l-menthol
Study: 28513852
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg orally before thrombolytic therapy)
Study: 28513852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard protocol for treatment of MI)
Study: 10936631
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment (IPT or NT)
Study: 2052740
Drug: Controlled-release hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release hydrogel polymer prostaglandin E2 pessary (0.6 mg PGE2 per hour)
Study: 6192652
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor blockade alone
Study: 6192652
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor blockade in combination with H2 receptor blockade
Study: 6192652
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor blockade alone
Study: 25847112
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antidepressants (mainly selective serotonin reuptake inhibitors)
Study: 19415289
Drug: Multidetector CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidetector CT after oral administration of polyethylene glycol solution (n = 21)
Study: 19415289
Drug: Multidetector CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidetector CT after administration of methylcellulose via nasojejunal tube (n = 13)
Study: 15145874
Drug: DDDR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDDR with fixed long AV delay (DDDR-l) (n = 63)
Study: 1700077
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus vinblastine plus bleomycin (PVB) chemotherapy
Study: 7377916
Drug: Naloxone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (20 mg, intravenous)
Study: 30783957
Drug: Baclofen 5%
Normalized name: Baclofen 5% Topical application Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 5% cream
Study: 31708152
Drug: Co-trimoxazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (20 mg trimethoprim and 100 mg sulfamethoxazole orally for infants <6 months or <5 kg; 40 mg trimethoprim and 200 mg sulfamethoxazole orally for infants >6 months or >5 kg)
Study: 27370878
Drug: Pirfenidone (801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (801 mg/day titrated to 2403 mg/day over 16 weeks)
Study: 27370878
Drug: Pirfenidone with
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone with 2-week titration
Study: 27370878
Drug: Pirfenidone with
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone with 4-week titration
Study: 24634424
Drug: Tactile stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactile stimulation (rubbing the skin adjacent to the injection site or applying pressure)
Study: 20669666
Drug: Intracoronary administering
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary administering of 10 mL (0.5 mg) tirofiban and 400 mg XST, followed by 36 h continuous intravenous dripping of tirofiban 10 mL/h and 400 mg XST in 250 mL of saline for dripping.
Study: 20669666
Drug: Intracoronary administering
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary administering of 10 mL (0.5 mg) tirofiban, followed by 36 h continuous intravenous dripping of tirofiban 10 mL/h without XST.
Study: 12164876
Drug: ET‐A receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐A receptor antagonist BQ‐123 (40 nmol/min)
Study: 12164876
Drug: ET‐B receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐B receptor antagonist BQ‐788 (1 and 50 nmol/min)
Study: 8352038
Drug: Silver acetate
Normalized name: SILVER ACETATE
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver acetate mouth spray, used every 2 hours for 3 weeks
Study: 8352038
Drug: Placebo spray,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray, used every 2 hours for 3 weeks
Study: 3676054
Drug: HFJV using
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFJV using three frequencies (100, 300 and 600 b.p.m.) via a 1.8‐mm i.d. proximal injector cannula (proximal injection)
Study: 30173835
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with a continuous beam 660-nm, 75-mW laser applied for 15 seconds at 8 points for a total treatment time of 2 minutes.
Study: 25044172
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (SLT) alone
Study: 15811140
Drug: DZX 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZX 100 mg three times daily for 6 days
Study: 15811140
Drug: DZX 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZX 50 mg three times daily for 6 days
Study: 15811140
Drug: DZX 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZX 75 mg three times daily for 6 days
Study: 15811140
Drug: DZX 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZX 50 mg in non-obese men
Study: 15811140
Drug: DZX 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZX 100 mg in non-obese men
Study: 6853873
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment program (4 weeks of coping-skills training using behavioral rehearsal and self-instruction training)
Study: 31347247
Drug: Esomeprazole (ESO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (ESO, 20 mg bid) (group A)
Study: 24406025
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ondansetron
Study: 20574649
Drug: ETN 25
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 25 mg twice a week and MTX 6‐8 mg/week (E + M group)
Study: 17310130
Drug: Pilocarpine 20
Normalized name: pilocarpine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 20 mg/day orally for 7 days
Study: 15883634
Drug: Fok1 polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fok1 polymorphism of the VDR with Ca intake >800 mg/day
Study: 15883634
Drug: Fok1 polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fok1 polymorphism of the VDR with Ca intake <= 800 mg/day
Study: 31821750
Drug: Itacitinib (10-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (10-300 mg, 500 mg, 1000 mg)
Study: 31196032
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg PO once daily for 6 months during SRT
Study: 25719991
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus prompt or deferred focal/grid laser treatment
Study: 25719991
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection plus focal/grid laser treatment
Study: 16438751
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg intravenously 3 min before induction of anaesthesia
Study: 9354348
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 800 mg daily
Study: 8222508
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (low dose: 1 ng min-1kg-1)
Study: 8222508
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (high dose: 5 ng min-1kg-1)
Study: 31898758
Drug: EMG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG biofeedback therapy applied to tibialis anterior muscles, 5 days a week for 3 weeks in addition to conventional physiotherapy
Study: 30956111
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration of ivermectin (200 μg/kg) and azithromycin (20 mg/kg)
Study: 30956111
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration of ivermectin and azithromycin
Study: 27840352
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (400 mg bid)
Study: 27840352
Drug: Phenazopyridine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine (200 mg tid)
Study: 27840352
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac (50 mg bid)
Study: 18285478
Drug: Amprenavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir (600 mg BID)
Study: 18285478
Drug: Lopinavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir (400 mg BID) plus ritonavir (100 or 200 mg BID)
Study: 18285478
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of amprenavir and lopinavir
Study: 12761806
Drug: Once-daily controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily controlled-release formulation of divalproex sodium
Study: 12761806
Drug: Commercial enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial enteric tablet dosed twice-daily
Study: 9118303
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg orally twice a day)
Study: 1714950
Drug: MOPP (mechlorethamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) alternating with ABVD (doxorubicin, vinblastine, bleomycin, and dacarbazine) followed by low-dose radiotherapy (RT)
Study: 1714950
Drug: MOPP alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP alternating with ABVD followed by low-dose RT
Study: 28423301
Drug: Risankizumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (90 mg and 180 mg doses at weeks 0, 4, and 16)
Study: 28423301
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 or 90 mg doses at weeks 0, 4, and 16)
Study: 28423301
Drug: Risankizumab (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (18 mg, 90 mg, and 180 mg doses)
Study: 28423301
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 or 90 mg doses)
Study: 24561125
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg once daily
Study: 21114607
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg once daily